Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Cardium Reveals New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology To Deliver Bone Growth Factors

Cardium Therapeutics (Cardium), a medical technology company, revealed plans to develop a DNA-based orthobiologics product portfolio based on research and development by its Tissue Repair Company. Cardium's Tissue Repair Company will initially focus on non-union bone fractures for medically-compromised patients, and spinal fusion for patients with degenerative disc disease.

Following on results observed with Tissue Repair’s Excellarate product candidate, which is targeted to the repair of soft tissues (particularly diabetic ulcers), the company’s orthobiologics initiative will build on and extend the underlying technology that has been developed by the Tissue Repair Company to hard tissue applications such as bone, including: (1) proprietary Gene Activated Matrix or GAM delivery and ligand targeting; (2) use of GAM to locally produce proteins capable of stimulating bone and other tissue growth; and (3) a substantial body of pre-clinical research and development supporting the use of GAM to deliver bone growth factors. Cardium believes that future DNA-based products offer the potential to provide patients and healthcare systems with more cost-effective alternatives to current and planned protein-based therapeutics.